CZEN 003

Drug Profile

CZEN 003

Alternative Names: CZEN-003

Latest Information Update: 13 Jul 2004

Price : $50

At a glance

  • Originator Zengen
  • Class
  • Mechanism of Action Alpha-MSH stimulants; Immunosuppressants; Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Transplant rejection

Most Recent Events

  • 13 Jul 2004 This compound is still in active development - BIO 2004 Annual International Convention (BIO-2004)
  • 16 Dec 2002 Preclinical trials in Transplant rejection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top